Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma

by Liu, Qingjun, Mier, James W, Panka, David J
Published 2011

PI3K inhibition potentiates Bcl-2-dependent apoptosis in renal carcinoma cells

by Zhu, Shudong, Cohen, Matthew B, Bjorge, Jeffrey D, Mier, James W, Cho, Daniel C
Published 2013

Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells

by Panka, David J, Liu, Qingjun, Geissler, Andrew K, Mier, James W
Published 2013

Novel drugs that target the metabolic reprogramming in renal cell cancer

by van der Mijn, Johannes C., Panka, David J., Geissler, Andrew K., Verheul, Henk. M., Mier, James W.
Published 2016

High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma

by Wang, Xiaoen, Zhang, Liang, Goldberg, S Nahum, Bhasin, Manoj, Brown, Victoria, Alsop, David C, Signoretti, Sabina, Mier, James W, Atkins, Michael B, Bhatt, Rupal S
Published 2011

Calpain Regulates Actin Remodeling during Cell Spreading

by Potter, David A., Tirnauer, Jennifer S., Janssen, Richard, Croall, Dorothy E., Hughes, Christina N., Fiacco, Kerry A., Mier, James W., Maki, Masatoshi, Herman, Ira M.
Published 1998

The Role of Angiopoietins as Potential Therapeutic Targets in Renal Cell Carcinoma1

by Wang, Xiaoen, Bullock, Andrea J., Zhang, Liang, Wei, Lin, Yu, Dongyin, Mahagaokar, Kedar, Alsop, David C., Mier, James W., Atkins, Michael B., Coxon, Angela, Oliner, Jon, Bhatt, Rupal S.
Published 2014

Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression

by Zhang, Liang, Bhasin, Manoj, Schor-Bardach, Rachel, Wang, Xiaoen, Collins, Michael P., Panka, David, Putheti, Prabhakar, Signoretti, Sabina, Alsop, David C., Libermann, Towia, Atkins, Michael B., Mier, James W., Goldberg, S. Nahum, Bhatt, Rupal S.
Published 2011

Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma

by Wang, Xiaoen, Solban, Nicolas, Khanna, Prateek, Callea, Marcella, Song, Jiaxi, Alsop, David C., Pearsall, R. Scott, Atkins, Michael B., Mier, James W., Signoretti, Sabina, Alimzhanov, Marat, Kumar, Ravi, Bhasin, Manoj K., Bhatt, Rupal S.
Published 2016

Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics

by Frederick, Dennie T., Salas Fragomeni, Roberto A., Schalck, Aislyn, Ferreiro-Neira, Isabel, Hoff, Taylor, Cooper, Zachary A., Haq, Rizwan, Panka, David J., Kwong, Lawrence N., Davies, Michael A., Cusack, James C., Flaherty, Keith T., Fisher, David E., Mier, James W., Wargo, Jennifer A., Sullivan, Ryan J.
Published 2014